|1.||Qi, Ming: 10 articles (10/2015 - 08/2010)|
|2.||van de Velde, Helgi: 10 articles (10/2015 - 05/2013)|
|3.||Reddy, Manjula: 10 articles (10/2015 - 09/2011)|
|4.||Qin, Xiang: 7 articles (10/2015 - 08/2010)|
|5.||van Rhee, Frits: 7 articles (10/2015 - 08/2010)|
|6.||Puchalski, Thomas A: 7 articles (05/2015 - 06/2013)|
|7.||Kurzrock, Razelle: 6 articles (01/2016 - 08/2010)|
|8.||Vermeulen, Jessica: 6 articles (10/2015 - 09/2011)|
|9.||Casper, Corey: 6 articles (10/2015 - 08/2010)|
|10.||Bandekar, Rajesh: 6 articles (10/2015 - 01/2014)|
12/01/2015 - "Relative to placebo, the addition of siltuximab to best supportive care improved tumor- and symptom-related outcomes, with patients also reporting improvements in MCD symptoms, functional status, and well-being. "
10/06/2015 - "Siltuximab, an anti-IL-6 monoclonal antibody, has demonstrated durable tumor and symptomatic responses in a multinational, randomized, placebo-controlled study of MCD. "
10/01/2014 - "In a recent randomized placebo-controlled Phase II trial, subjects with HIV-negative, HHV8-negative MCD who received siltuximab demonstrated a significantly higher rate of durable tumor and symptomatic response with a tolerable safety profile, leading to its approval for the treatment of HIV-negative HHV8-negative MCD by the US FDA and the European Commission in April and May 2014, respectively. "
04/15/2014 - "A phase I/II, multiple-dose, dose-escalation study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with advanced solid tumors."
07/01/2014 - "We examined the influence of cancer-associated fibroblasts (CAFs) on tumor growth and siltuximab effects. "
03/01/2015 - "Phase 1 study in Japan of siltuximab, an anti-IL-6 monoclonal antibody, in relapsed/refractory multiple myeloma."
05/01/2013 - "A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma."
03/01/2010 - "Starting-dose selection for this study was based on a previous siltuximab study in multiple myeloma patients. "
07/01/2013 - "In an open-label, dose-finding, 7 cohort, phase I study, patients with NHL, multiple myeloma, or symptomatic Castleman disease received siltuximab 3, 6, 9, or 12 mg/kg weekly, every 2 weeks, or every 3 weeks. "
05/01/2015 - "PK/PD modeling was applied to explore the relationship between siltuximab PK and CRP suppression following intravenous siltuximab infusion in 47 patients with B cell non-Hodgkin's lymphoma (n = 17), multiple myeloma (n = 13), or CD (n = 17). "
|3.||Lung Neoplasms (Lung Cancer)
07/01/2014 - "Antitumor efficacy of the anti-interleukin-6 (IL-6) antibody siltuximab in mouse xenograft models of lung cancer."
03/01/2011 - "Siltuximab could completely inhibit STAT3 tyrosine phosphorylation in H1650 cells, and this resulted in inhibition of lung cancer cell growth in vivo. "
07/01/2014 - "We examined IL-6/STAT3 in lung cancer tumor tissues and the effects of siltuximab, a neutralizing antibody to human IL-6, in mouse models of lung cancer. "
03/01/2011 - "Combined EGFR inhibition with erlotinib and siltuximab resulted in dual inhibition of both tyrosine and serine STAT3 phosphorylation, more pronounced inhibition of STAT3 transcriptional activity, and translated into combined effects on lung cancer growth in a mouse model. "
|4.||Prostatic Neoplasms (Prostate Cancer)
09/15/2011 - "This study was designed to assess preliminary safety of siltuximab in patients with early prostate cancer. "
09/15/2011 - "The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study."
09/15/2011 - "Siltuximab (CNTO 328) is a monoclonal anti-IL-6 antibody which has been successfully applied in several models representing prostate cancer. "
09/15/2011 - "Future studies in which siltuximab could be combined with androgen-deprivation therapy and experimental therapies in advanced prostate cancer are justified."
06/01/2010 - "We conducted a multicenter phase II study of CNTO328 (siltuximab) as second-line therapy for men with castration-resistant prostate cancer. "
|5.||Giant Lymph Node Hyperplasia (Castleman's Disease)
01/01/2015 - "Results from this study led to the recent approval of siltuximab for the treatment of Castleman's disease by the FDA and EMA. "
01/01/2016 - "Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease."
12/01/2015 - "Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease."
10/15/2015 - "Siltuximab for Multicentric Castleman Disease-Letter."
03/01/2015 - "FDA approval: siltuximab for the treatment of patients with multicentric Castleman disease."
|1.||Interleukin-6 (Interleukin 6)
|8.||STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)
|9.||Biological Markers (Surrogate Marker)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)
|4.||Investigational Therapies (Experimental Therapy)